PDS Planning Inc Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

PDS Planning Inc increased its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 50.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 15,759 shares of the company’s stock after purchasing an additional 5,316 shares during the period. PDS Planning Inc’s holdings in Takeda Pharmaceutical were worth $209,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its stake in Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares in the last quarter. Stifel Financial Corp boosted its holdings in Takeda Pharmaceutical by 103.9% during the 3rd quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after acquiring an additional 224,594 shares during the period. Crossmark Global Holdings Inc. grew its position in Takeda Pharmaceutical by 284.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after acquiring an additional 155,795 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Takeda Pharmaceutical during the fourth quarter worth about $1,447,000. Finally, Verition Fund Management LLC purchased a new position in shares of Takeda Pharmaceutical in the third quarter valued at approximately $1,533,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock opened at $15.14 on Thursday. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.24. The firm has a 50 day moving average of $13.87 and a two-hundred day moving average of $13.91. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $48.16 billion, a PE ratio of 37.84, a P/E/G ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.